secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001809519-24-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx pre-announces Q4 revenue above guidance; expects mid-single-digit growth in 2024
--------------------------------------------------------------------------------

- Q4 2023 revenue and adjusted revenue expected $195-197M, up ~6-7% YoY and above prior guidance.
- FY 2023 revenue expected $749-751M (-~2% YoY); adjusted revenue $759-761M (-~1% YoY).
- Q4 outperformance driven by organic growth in Prescription Transactions, stronger respiratory season and favorable contracts.
- Early 2024 outlook: Q1 and FY revenue and adjusted revenue to grow mid-single digits YoY; adjusted EBITDA margin in high-twenty% range.
- Full Q4 and 2024 guidance to be provided on February earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000006/0001809519-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000180951924000006/gdrx-20240110.htm
  HTML page:      https://secwatch.observer/filing/0001809519-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer